Stock A144510 GC CELL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials GC Cell Corporation

Equities

A144510

KR7144510005

Healthcare Facilities & Services

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
37,600 KRW +0.53% Intraday chart for GC Cell Corporation +4.16% -17.36%
Feb. 26 GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj CI
Jan. 08 GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 484,431 399,999 972,028 1,606,895 708,035 683,530
Enterprise Value (EV) 1 456,144 393,699 967,039 1,656,756 735,710 762,403
P/E ratio 483 x -176 x 234 x 36.5 x 29.1 x -3,792 x
Yield 0.08% 0.07% 0.11% - 0.74% 0.22%
Capitalization / Revenue 9.57 x 6.91 x 11.4 x 9.55 x 3 x 3.64 x
EV / Revenue 9.01 x 6.8 x 11.3 x 9.84 x 3.12 x 4.07 x
EV / EBITDA 352 x 453 x 91.7 x 37.8 x 12.7 x 38.7 x
EV / FCF - -164,619,823 x 487,429,128 x -150,333,076 x 14,997,349 x -31,306,948 x
FCF Yield - -0% 0% -0% 0% -0%
Price to Book 10.2 x 9.08 x 20.6 x 2.99 x 1.31 x 1.28 x
Nbr of stocks (in thousands) 10,554 10,554 10,554 15,800 15,017 15,023
Reference price 2 45,900 37,900 92,100 101,700 47,150 45,500
Announcement Date 3/16/20 3/16/20 3/16/21 3/18/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 50,620 57,895 85,562 168,310 236,120 187,544
EBITDA 1 1,296 868.5 10,545 43,802 57,897 19,719
EBIT 1 327.8 -3,245 6,364 36,407 44,274 4,079
Operating Margin 0.65% -5.6% 7.44% 21.63% 18.75% 2.18%
Earnings before Tax (EBT) 1 859.2 -3,374 5,383 39,533 36,508 -7,464
Net income 1 1,002 -2,276 4,160 31,422 24,991 -174
Net margin 1.98% -3.93% 4.86% 18.67% 10.58% -0.09%
EPS 2 94.95 -215.6 394.2 2,784 1,622 -12.00
Free Cash Flow - -2,392 1,984 -11,021 49,056 -24,353
FCF margin - -4.13% 2.32% -6.55% 20.78% -12.98%
FCF Conversion (EBITDA) - - 18.81% - 84.73% -
FCF Conversion (Net income) - - 47.69% - 196.3% -
Dividend per Share 2 35.00 25.00 100.0 - 350.0 100.0
Announcement Date 3/16/20 3/16/20 3/16/21 3/18/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income -
Net margin -
EPS 1 196.0
Dividend per Share -
Announcement Date 11/14/23
1KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 49,861 27,675 78,872
Net Cash position 1 28,287 6,300 4,989 - - -
Leverage (Debt/EBITDA) - - - 1.138 x 0.478 x 4 x
Free Cash Flow - -2,392 1,984 -11,021 49,056 -24,353
ROE (net income / shareholders' equity) - -4.67% 8.21% 10.6% 4.85% 0.01%
ROA (Net income/ Total Assets) - -3.24% 5.51% 6.3% 4.19% 0.38%
Assets 1 - 70,330 75,527 498,472 597,024 -45,792
Book Value Per Share 2 4,522 4,174 4,469 34,029 35,857 35,548
Cash Flow per Share 2 2,206 1,288 864.0 1,199 3,155 836.0
Capex 1 4,780 5,344 4,788 10,876 6,915 11,397
Capex / Sales 9.44% 9.23% 5.6% 6.46% 2.93% 6.08%
Announcement Date 3/16/20 3/16/20 3/16/21 3/18/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
GC CELL CORPORATION Stock GC Cell Corporation
-17.36% 410M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.89% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.46B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.35% 2.38B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-12.61% 1.81B
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. A144510 Stock
  4. Financials GC Cell Corporation